Alert detail
FDA Approval: ZANVASTRO (ZILGANERSEN) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA220210Specialty: NeurologyAdded: 9/9/2026Effective: September 3, 2026federal register
What changed
Zanvastro injection flagged Part D—verify pathway against FDA label.
Who’s affected: Neurology billing teams · Effective: September 3, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.